46.53 0.00 (0.00%)
After hours: 5:00PM EDT
|Bid||46.67 x 800|
|Ask||46.54 x 900|
|Day's Range||46.51 - 47.68|
|52 Week Range||39.64 - 73.89|
|Beta (3Y Monthly)||1.68|
|PE Ratio (TTM)||58.02|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||68.67|
Emergent BioSolutions CEO Robert Kramer Sr. sits down with Yahoo Finance's Dan Roberts, Melody Hahm and Myles Udland on "YFi AM" to discuss the fight over drug pricing and hear how the biopharmaceutical company is seeking to make Narcan, a life-saving drug that blocks the effects of an opioid overdose, more affordable and accessible.
Emergent Biosolutions Inc NYSE:EBSView full report here! Summary * Bearish sentiment is low and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for EBS with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on May 14. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold EBS had net inflows of $1.16 billion over the last one-month. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
If you're interested in Emergent BioSolutions Inc. (NYSE:EBS), then you might want to consider its beta (a measure of...
, the vaccine maker with shares that are off 23% for the year amidst fears of a crackdown on drug prices. Kramer explained that Emergent began in 1998 in order to protect people from public health threats.
Good things can still happen in the stock market, Jim Cramer assured his Mad Money viewers Tuesday, but don't get overconfident, because bad things can still happen too. Cramer said once again, the proprietary S&P 500 oscillator he follows was correct, and the markets were a coiled spring ready to rally higher. Cramer said all of these positive trends, combined with a market that had gotten severely oversold, left few sellers to be found today.
The PAS supports the change in storage conditions of the vaccine from frozen to refrigerated at 2-8°C and the transfer of bulk drug substance manufacturing from Emergent’s product development facility in San Diego to its manufacturing facility in Bern, Switzerland. The company’s oral cholera vaccine is the only FDA-licensed vaccine for the prevention of cholera caused by Vibrio cholerae serogroup O1, a potentially serious intestinal disease.
Shares of Emergent (EBS) rise after the company gets a 10-year HHS contract valued at roughly $535 million to dispense VIGIV product to the U.S. government for supporting its smallpox awareness drive.
The product is the only therapy approved by the Food and Drug Administration for smallpox vaccine complications.
Emergent BioSolutions Inc. (EBS) today announced a contract award by the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) valued at approximately $535 million over 10 years for the continued supply of Vaccinia Immune Globulin Intravenous (VIGIV) into the U.S. Strategic National Stockpile (SNS) in support of smallpox preparedness. “Emergent is pleased to continue its successful track record of being a solutions provider to governments to help address serious public health threats such as smallpox,” said Robert G. Kramer Sr., president and chief executive officer of Emergent BioSolutions.
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Investors are always looking for growth in small-cap stocks like Emergent BioSolutions Inc. (NYSE:EBS), with a market...
GAITHERSBURG, Md., May 20, 2019 -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has successfully obtained marketing authorization for its oral typhoid vaccine.
GAITHERSBURG, Md., May 20, 2019 -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the.
Emergent BioSolutions Inc. (EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA) has informed the company that it will begin procuring AV7909 (anthrax vaccine adsorbed with CPG 7909 adjuvant) for delivery into the Strategic National Stockpile (SNS). Subject to the fulfillment of certain contractual obligations, the company plans to deliver AV7909 in the second half of 2019 under the terms of its development and procurement contract with BARDA valued at up to $1.5 billion signed in September 2016. This milestone and the initiation of the Phase 3 trial of AV7909 in March build upon the application that was submitted in December 2018 to the U.S. Food and Drug Administration (FDA) for the potential emergency use of AV7909 in the event of a public health emergency involving Bacillus anthracis.
GAITHERSBURG, Md., May 09, 2019 -- Emergent BioSolutions Inc. (NYSE: EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 23, 2019 beginning.